Release Date: November 7, 2025
CME Track Expiration Date: November 7, 2026
Pharmacist Track Expiration Date: February 28, 2027
Activity Overview
Oncology nurses are pivotal members of health care teams in managing new and complex therapies. Their role in patient monitoring, education, and intervention is essential for achieving successful treatment outcomes with antibody-drug conjugates (ADCs). Nurses are uniquely positioned to identify early signs of toxicities, educate patients on possible adverse events, and help mitigate those risks via early medical intervention.
However, many nurses have not received comprehensive education on the relevant biomarkers of ADCs, their mechanisms of action, and the management of adverse events. Given the rapid introduction of ADCs into the clinical landscape, it is critical to address these gaps through continuing education programs. This educational symposium, targeted at oncology nurses, will help bridge these gaps, enabling nurses to provide better patient care and improve clinical outcomes.
This educational activity is an archive of the live presentation held on October 26, 2025.
For more information about this educational activity, the faculty, and disclosures, please click here.
Target Audience
This educational activity is directed toward oncology nurses and nurse practitioners/physician assistants who care for patients with solid tumors.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Discuss the role of ADC therapeutic targets in solid tumors
- Interpret findings from recent clinical trials on ADC therapies and their implications for advanced practice providers
- Apply evidence-based strategies to monitor and manage ADC-specific adverse events during and after treatment
- Describe the clinical considerations of ADC therapy needed to effectively counsel patients
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login HereAccreditation/Credit Designation
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians' Education Resource®, LLC (PER) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.
Physicians' Education Resource®, LLC has approved this application-based activity for 1.50 ACPE CE hours UAN# 0661-0000-25-017-H01-P. Eligibility for credits requires full engagement with the enduring activity, completion, and submission of the learner’s NABP ID # and month and day of birth, activity pre- and post-session questions, and the post-activity evaluation. This UAN # expires February 28, 2027.
Acknowledgment of Commercial Support
This activity is supported by educational grants from Daiichi Sankyo, Inc; and Merck Sharp & Dohme LLC.